niacinamide semaglutide for weight loss And Together Let’s Stop the Shame: A

Additional information Peer review information Nature Communications thanks Olivier Schwartz and the other anonymous reviewer(s) for their contribution to the peer review of this work

The article says published literature on GLP-1 agonists in breastfeeding is extremely limited, most prescribing information states lactation data is unavailable, and there are no large human trials

You must also meet at least one of the following body mass index (BMI) requirements at the time you start GLP-1 therapy: A BMI of 35 or higher A BMI between 3034.99 with at least one qualifying condition, such as diastolic heart failure, uncontrolled high blood pressure, chronic kidney disease at stage 3a or higher, prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms A BMI between 2729.99 with prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms Who does NOT qualify

Safety is well-established at standard research doses